Comorbidity status and interleukin-10 levels in end-stage renal disease patients treated with hemodialysis.

Unlabelled: It has been proven that the activity of chronic inflammation is one of the leading factors in the development of comorbid pathology in endstage renal disease (ESRD) patients. However, the clinical significance of anti-inflammatory mediators in this patient population has been studied quite limited. Study the role of IL-10 in the pathogenesis of comorbidity, due to its inherent properties, causes great interest.

[POSITIVE EFFECTS OF MODERN IMMUNOCORRECTION ACCORDING TO THE ANALYSIS OF CYTOKINES AND SLPI IN PATIENTS WITH PYELONEPHRITIS].

The peculiarities of cytokines as compounds of immunogenesis are shown in the patients having acute (A) and chronic (Ch) pyelonephritis (PN). The combination of antibacterial therapy with Nukleinat and Galavit promotes the positive changes of cytokin-producing ability of immunocompetent cells and decrease in the level of proinflammation cytokines in blood and urine, secretory leucocyte protease inhibitor (SLPI) in urine. In children with PN and adult patients with diagnostically elevated titres of antibodies (IgG) to Herpes simplex virus, Cytomegalovirus are shown the positive effects of Kanephron® H and Proteflazidum, accordingly.